Daily Brief Health Care: CSL Ltd, ClouDr Group, Insulet Corp, Oryzon Genomics and more

• CSL Ltd (CSL AU) is well-positioned to report double-digit revenue and profit growth through FY25, driven by strong performance of existing business and new growth engines.
• CSL will launch FDA-approved gene therapy Hemgenix for Hemophilia B in the US in 2H23. With estimated global annual peak sales of $2.4B, Hemgenix is a compelling opportunity for CSL.
• During H1FY23, CSL reported record level of plasma collections, with 36% growth in                volume. Current plasma collection is 10% above the pre-pandemic. Higher volume and yield will improve profitability.

• ClouDr had outstanding performance in 2022, which was mainly due to its unique but effective development model – starting from To B business first and then expanding To C business. 
• ClouDr may become the first company to develop a successful profit model of online medical services. The integration of AI and medical care enables ClouDr to enjoy more policy dividends/catalysts 
• ClouDr Group (9955 HK) has high growth potential with big investment value, and it could even surpass JD Health in the future. The Company is undervalued and deserve investors’ attention.

• Insulet Corporation is a med-tech company and one of the largest insulin delivery systems providers in the world.
• Their Omnipod 5 Automated Insulin Delivery System’s complete commercial introduction in 2022 was a major accomplishment.
• Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.

• This is our first report on a Insulet Corporation, one of the largest insulin delivery systems providers in the world.
• Their Omnipod 5 Automated Insulin Delivery System’s complete commercial introduction in 2022 was a major accomplishment.
• We initiate coverage on the stock of Insulet Corporation with a ‘Hold’ rating.

Oryzon has announced promising results from an interim analysis of the Phase IIb PORTICO study, a trial evaluating vafidemstat as a treatment for borderline personality disorder (BPD). An independent data monitoring committee (IDMC) conducted an analysis of the first 90 patients who completed the treatment and recommended that the trial continue without any modifications to the design. These interim results, along with positive safety data reported in September 2022, are encouraging for the clinical development of vafidemstat in this indication, in our view. Management anticipates that top-line data will be shared in early 2024 and we believe this represents the next most significant catalyst for the PORTICO trial.